GLP 1s effectiveness at blood pressure control on par with traditional anti hypertensives, tracks well with % weight loss. In someone with hypertension due to their underlying obesity, why not Michael Weintraub, MD Retatrutide + Cagrilintide: The Weight Loss Stack Outperforming Ozempic [2026 Protocol] In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Mazdutide vs Tirzepatide vs Semaglutide: Comparative Efficacy Ney Carter Borges MD M.Sc. Ph.D FESC,FACC,FAHA,FACP. posted on the topic LinkedIn Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY 2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity